In short: lurbinectedin can affect the reproductive system mainly through risks to a developing fetus and, because it is a chemotherapy drug, by potentially impacting fertility. The exact risks for fertility are not fully defined in humans, but the drug’s cytotoxic nature means there is some potential for gonadal effects with cancer chemotherapy in general. Here’s what is typically known and advised:
What is known about reproductive risks
- Pregnancy and fetal harm: Lurbinectedin can cause embryo-fetal toxicity. It can harm a developing fetus if a person is pregnant while receiving the drug.
- Fertility: Data in humans are limited. Chemotherapy drugs can sometimes lead to temporary or permanent infertility in both women and men, depending on the drug, dose, and duration. While specific rates for lurbinectedin aren’t well established, gonadal toxicity is a recognized risk with many cytotoxic agents.
- Menstrual changes: Some female patients may experience changes in menstrual periods, including irregularity or amenorrhea, during or after chemotherapy in general (not guaranteed with every drug).
- Male fertility: Sperm production can be affected by chemotherapy in some cases, potentially reducing fertility. Sperm banking before starting therapy is commonly discussed for patients who may want to preserve fertility.
What is typically recommended (based on labeling and standard practice)
- For people who can become pregnant: use effective contraception during treatment and for a specified period after the last dose (the exact duration is stated in the product labeling; typically several months). If pregnancy occurs, contact the treating physician immediately.
- For people who can father a child: use contraception during treatment and for the recommended period afterward as advised by the label, and discuss fertility preservation if desired.
- Breastfeeding: not recommended during treatment, due to potential drug exposure to the infant.
- Fertility counseling: if future fertility is a concern, discuss options (e.g., egg or embryo freezing for people with ovaries, or sperm banking for people with testes) before starting therapy.
Important caveats
- The precise contraception durations and any paternal exposure guidance come from the official drug labeling. If you or someone you care for is on lurbinectedin, check the current label or talk with the prescribing oncologist or a pharmacist for the exact recommendations.
- Individual risk can vary based on dose, schedule, other medications, overall health, and whether there is concurrent radiation or other chemotherapy.
If you’d like, tell me:
- Are you asking about a specific patient (female or male) or planning for future fertility?
- Is the patient currently undergoing lurbinectedin therapy, or is this planning before starting treatment?
I can tailor the information (and suggest fertility preservation options or relevant specialists) to the situation.